{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=24", "query": { "intervention": "Monoclonal antibody - Dose Escalation", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 886, "total_pages": 89, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Monoclonal+antibody+-+Dose+Escalation&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T04:51:35.002Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04423029", "title": "A Study of DF6002 Alone and in Combination With Nivolumab", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "DF6002", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dragonfly Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 170, "start_date": "2020-07-13", "completion_date": "2025-11-26", "has_results": false, "last_update_posted_date": "2026-03-18", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 21, "location_summary": "Orange, California • Denver, Colorado • New Haven, Connecticut + 17 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04423029" }, { "nct_id": "NCT07225439", "title": "Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "B-cell Non Hodgkin Lymphoma", "Diffuse Large B Cell Lymphoma", "High-grade B-cell Lymphoma", "Primary Mediastinal Large B Cell Lymphoma", "Follicular Lymphoma", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Allogeneic NK cells", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Interleukin-2", "type": "DRUG" }, { "name": "Fludarabine/cyclophosphamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Paolo Caimi, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2026-09", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 2, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07225439" }, { "nct_id": "NCT02675439", "title": "Safety and Efficacy of MIW815 (ADU-S100) +/- Ipilimumab in Patients With Advanced/Metastatic Solid Tumors or Lymphomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced/Metastatic Solid Tumors or Lymphomas" ], "interventions": [ { "name": "ADU-S100", "type": "DRUG" }, { "name": "ipilimumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Chinook Therapeutics, Inc. (formerly Aduro)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 47, "start_date": "2016-04-28", "completion_date": "2020-08-06", "has_results": false, "last_update_posted_date": "2021-12-30", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 7, "location_summary": "Aurora, Colorado • Chicago, Illinois • Baltimore, Maryland + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02675439" }, { "nct_id": "NCT00147537", "title": "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Carcinoma, Non-Small-Cell Lung" ], "interventions": [ { "name": "CP-751,871", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 282, "start_date": "2005-02", "completion_date": "2011-08", "has_results": true, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 26, "location_summary": "Tucson, Arizona • Greenbrae, California • Los Angeles, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00147537" }, { "nct_id": "NCT02350751", "title": "Phase 1 Placebo-controlled,Dose-escalation Study to Evaluate the Safety and Pharmacokinetics of MEDI8852 in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Influenza" ], "interventions": [ { "name": "MEDI8852", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 94, "start_date": "2015-01", "completion_date": "2015-06", "has_results": false, "last_update_posted_date": "2015-07-13", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 1, "location_summary": "Overland Park, Kansas", "locations": [ { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02350751" }, { "nct_id": "NCT06381141", "title": "A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "CLN-619", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cullinan Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2024-09-03", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2025-09-18", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 8, "location_summary": "Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 4 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06381141" }, { "nct_id": "NCT00775502", "title": "Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BIW-8962", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyowa Kirin Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 23, "start_date": "2008-10", "completion_date": "2011-10", "has_results": false, "last_update_posted_date": "2024-04-25", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 5, "location_summary": "Tampa, Florida • Chicago, Illinois • Detroit, Michigan + 2 more", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00775502" }, { "nct_id": "NCT03740529", "title": "A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chronic Lymphocytic Leukemia", "Waldenstrom Macroglobulinemia", "Mantle Cell Lymphoma", "Marginal Zone Lymphoma", "B-cell Lymphoma", "Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Pirtobrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Loxo Oncology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 803, "start_date": "2019-03-15", "completion_date": "2025-12-23", "has_results": false, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 31, "location_summary": "Scottsdale, Arizona • San Diego, California • San Francisco, California + 25 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03740529" }, { "nct_id": "NCT03024437", "title": "Atezolizumab in Combination With Entinostat and Bevacizumab in Patients With Advanced Renal Cell Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Cancer", "Renal Cancer" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Entinostat", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roberto Pili", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2017-06-29", "completion_date": "2024-06-24", "has_results": true, "last_update_posted_date": "2025-03-20", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 4, "location_summary": "Indianapolis, Indiana • Columbus, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03024437" }, { "nct_id": "NCT01400451", "title": "Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Ipilimumab (BMS-734016)", "type": "DRUG" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-11", "completion_date": "2013-12", "has_results": true, "last_update_posted_date": "2015-01-01", "last_synced_at": "2026-10-15T04:51:35.002Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01400451" } ] }